News

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development.

The presentations from the 4th International Workshop on Clin. Pharm. of TB Drugs are available [click here].

Key abstracts from ICAAC were:

Authors Abstract Title
  • Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg

Pyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
  • A. Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg
Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB
  • R. Tasneen, S. Li, K. Andries, K. Mdluli, E. Nuermberger
Novel TMC207-containing Regimens Have Sterilizing Activity In Murine Tuberculosis
  • H. Huang , K. Liu, D. Zhang, B. Liu, G. Zhang, H. Zhang, Y. Li, Master C. Zhang, Y. Liu, J. Wang, Y. Lu, M. Zheng, B. Wang, T. Yang, X. Li, C. Li, C. B. Cooper, Z. Ma, D. Yin
SAR of Riminophenazine Class and Discovery of New Anti-tuberculosis Agents Active Against Multidrug-Resistant Tuberculosis
  • Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, D. Yin, H. Huang, Z. Ma

Clofazimine Analogs with Superior Efficacy against Experimental Tuberculosis and Reduced Potential

for Tissue Discoloration

  • M. Upton, A. Shadiack, Z. Ma, Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu,
  • H. Jin, D. Yin, H. Huang
Anti-tubercular Clofazimine Analogs that Demonstrate a Range of Tissue Distribution Patterns Following Eight Weeks Dosing to Mice
  • K. C. Chang, W. W. Yew, S. W. Cheung, C. C. Leung
Extensively Drug-resistant Tuberculosis (XDR-TB) Treated with Daily/ Intermittent Linezolid
  • L. Manzini, M. Parracino, D. Iemmi, G. Lapadula, A. Gori, E. Girardi, C. Mussini
Tolerability of Moxifloxacin as Part of Anti-Tuberculous Treatment

Additional TB R&D News:

Epistem successfully completes first-round testing of TB diagnostic device

Lilly Launches Open Innovation Drug Discovery Platform to Help Find Potential New Medicines Where Medical Need is Great

Open Innovation Drug Discovery [Actual Website]

Drug-Evading Tuberculosis Shows Rising Superbug Threat in China


More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...